Immediate vs. Delayed Postpartum Etonogestrel Implant
Summary
Linked Publications
-
Immediate versus delayed postpartum insertion of contraceptive implant and IUD for contraception.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Continuation Rate |
27; 21 | — |
| SECONDARY Rate of Intercourse |
8; 14 | — |
| SECONDARY Continuation Rate |
27; 21 | — |
Eligibility Criteria
Inclusion Criteria
1)Age 12-40 years 2)Must deliver at Duke Hospital 3)Must have a working telephone number 4)No contraindications to receiving this method of contraception, which include: known or suspected pregnancy, active liver disease or hepatic tumor, current or past history of thrombosis or thromboembolic disorder, undiagnosed abnormal genital bleeding, known or suspected breast cancer or history of breast cancer, hypersensitivity to any of the components of the device.
-
Exclusion Criteria
- Not meeting inclusion criteria
- Use of chronic medical therapy that has an adverse interaction with etonogestrel. Medications that will be cause for exclusion from the study include:
- Non-nucleoside reverse transcriptase inhibitors 2. ritonavir-boosted protease inhibitors 3. Certain anticonvulsants - phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine 4. Rifampin 5. St. John's Wort
-
Data sourced from ClinicalTrials.gov (NCT01767285) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.